SINGULERA
LIVE

Serial Number

50145475

Owner

Singulera Therapeutics Inc.

Attorney

Angel Roman Campos

Filing Date

Oct 5, 2026

Add to watchlist:

No watchlists yet
View on USPTO

SINGULERA Trademark

Serial Number: 50145475

SINGULERA is a trademark filed by Singulera Therapeutics Inc. on October 5, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Singulera Therapeutics Inc. (3 trademarks)

400 N. Aberdeen St, Suite 900
Chicago, IL 60642

Entity Type: 03

Trademark Details

Filing Date

October 5, 2026

Registration Date

Not Registered

Goods & Services

Custom manufacturing of pharmaceuticals; Custom manufacturing of biological tissue, blood, cell and genetic material; Custom manufacturing of biological preparations; Custom biomanufacturing of pharmaceutical preparations; Custom biomanufacturing of pharmaceuticals containing cultured cells for use in cell therapy; Custom manufacturing of cell therapy preparations; Contract biomanufacturing in the field of pharmaceuticals

Syringes sold filled with pharmaceuticals for the treatment of osteoarthritis and other degenerative joint diseases; Syringes sold filled with pharmaceuticals for chronic wound healing, including non-healing ulcers; Syringes sold filled with immune-modulating pharmaceuticals for autoimmune diseases and transplant rejection prevention; Syringes sold filled with pharmaceuticals for cardiovascular diseases, including acute myocardial infarction and ischemic conditions; Syringes sold filled with regenerative pharmaceuticals for skin and tissue repair; Organotherapy preparations; Biological preparations for use in cell cultures for medical purposes; Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Pharmaceutical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; Pharmaceutical preparations for cell therapy for medical purposes; Pharmaceutical preparations for gene therapy for medical purposes; Pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; Pharmaceutical preparations for therapies to modulate the immune system; Pharmaceutical preparations for therapeutic delivery of nucleic acids; Medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Stem cells for medical purposes; Opotherapy preparations; Biological reagent for medical purposes; Immunostimulants

Biological research; Biotechnological research; Medical research; Research and development of new products for others; Technological research in the field of biotechnology; Conducting technical project studies; Industrial research in the field of biotechnology; Research and development of pharmaceutical preparations; Conducting clinical trials for others; Research and development in the field of cell therapy; Research and development in the field of biopharmaceuticals; Research and development of pharmaceutical manufacturing processes; Research and development of biopharmaceutical manufacturing processes; Testing and analysis of pharmaceutical products

Medical services; Medical and pharmaceutical consultation; Providing medical information; Stem cell therapy services; Immunotherapy services; Medical treatment services for autoimmune diseases; Medical services for the prevention and treatment of organ transplant rejection

Filing History

APPLICATION FILING RECEIPT MAILED
Oct 5, 2026 MAFR
NEW APPLICATION ENTERED
Oct 5, 2026 NWAP